A5080819476- Pancreatic function and diabetes
- Diabetes Management and Research
- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Diabetes Treatment and Management
- Diabetes and associated disorders
- Metabolism, Diabetes, and Cancer
- SARS-CoV-2 and COVID-19 Research
- Liver Disease Diagnosis and Treatment
- Cardiovascular Function and Risk Factors
- Cellular transport and secretion
- Pediatric Hepatobiliary Diseases and Treatments
- COVID-19 diagnosis using AI
- Wound Healing and Treatments
- Gastrointestinal disorders and treatments
- Pancreatitis Pathology and Treatment
- Adenosine and Purinergic Signaling
- Clinical Nutrition and Gastroenterology
- COVID-19 Clinical Research Studies
- COVID-19 Impact on Reproduction
- Gastrointestinal Tumor Research and Treatment
- Immune Cell Function and Interaction
- Neurological and metabolic disorders
- Amoebic Infections and Treatments
- Diabetic Foot Ulcer Assessment and Management
Ospedale Versilia
2021-2024
Azienda Usl Toscana Centro
2023
University of Pisa
2009-2021
Azienda Ospedaliera Universitaria Pisana
2010-2017
Azienda Ospedaliera Sant'Andrea
2017
Sapienza University of Rome
2017
Ospedale Cisanello
2011
Although combined pancreas and kidney transplantation is an established procedure for the treatment of type 1 diabetes (T1D) in patients with end-stage renal disease, role transplant alone (PTA) therapy T1D subjects preserved function still matter debate.We report our single-center experience PTA 71 consecutive all a posttransplant follow-up 5 years. Patient (normoglycemia absence any antidiabetic therapy) survivals were determined, several clinical parameters (including risk factors...
The Review of Diabetic Studies,2011,8,2,259-267.DOI:10.1900/RDS.2011.8.259Published:August 2011Type:Original ArticleAuthors:Ugo Boggi, Fabio Vistoli, Gabriella Amorese, Rosa Giannarelli, Alberto Coppelli, Rita Mariotti, Lorenzo Rondinini, Massimiliamo Barsotti, Piaggesi, Anna Tedeschi, Stefano Signori, Nelide De Lio, Margherita Occhipinti, Emanuela Mangione, Diego Cantarovich, Del Prato, Franco Mosca, and Piero Marchetti Author(s) affiliations:Ugo Boggi1, Vistoli1, Amorese1, Giannarelli2,...
Abstract The intracellular life of insulin secretory granules (ISGs) from biogenesis to secretion depends on their structural (e.g. size) and dynamic diffusivity, mode motion) properties. Thus, it would be useful have rapid robust measurements such parameters in living β-cells. To provide measurements, we developed a fast spatiotemporal fluctuation spectroscopy. We calculate an imaging-derived Mean Squared Displacement ( i MSD), which simultaneously provides the size, average anomalous...
Duodenal graft complications are poorly reported of pancreas transplantation that can result in loss. Excluding patients with early failure, after a median follow-up period 126 months (range 23-198) duodenectomy was required 14 312 transplants (4.5%). All were insulin-independent at the time diagnosis. Reasons for included delayed duodenal perforation (n = 10, 71.5%) and refractory bleeding 4, 28.5%). In bleeding, total performed. perforation, preservation segment possible five but...
Despite the success rate of solitary pancreas transplantation in type 1 diabetes with preserved kidney function has greatly improved recent years, a residual proportion failures persists.With aim investigating autoimmunity as an unrecognized cause graft failure, we measured autoantibodies to glutamic acid decarboxylase (GADA), insulinoma-associated protein 2 (IA-2A) and recently discovered zinc transporter 8 antigen (ZnT8A) 25 recipients technically successful transplantation.The overall...
To search for clues suggesting that beta cells may generate by transdifferentiation in humans, we assessed the presence of double positive exocrine (amylase, carboxypeptidase A) and endocrine (insulin) markers pancreas non-diabetic individuals (ND) patients with type 2 diabetes (T2D). Samples from twelve ND matched T2D multiorgan donors were studied electron microscopy, including amylase insulin immunogold labeling; A immunofluorescence light microscopy assessment was also performed. In four...
Abstract Aims The revolution in the therapeutic approach to type 2 diabetes (T2D) requires a rethinking of positioning basal insulin (BI) therapy. Given considerable number open questions, group experts was convened with aim providing, through Delphi consensus method, practical guidance for doctors. Methods A 6 developed series 29 statements on: role metabolic control light most recent guidelines; BI intensification strategies: (1) add-on versus switch; (2) inertia starting and titrating;...
Physiologically regulated insulin secretion and euglycemia are achievable in type 1 diabetes (T1D) by islet or pancreas transplantation. However, transplant alone (PTA) remains a debated approach, with uncertainties on its relative benefits risks. We determined the actual long-term (10 y) efficacy safety of PTA carefully characterized T1D subjects.
Vistoli, F.1; Focosi, D.2; Duquesnoy, R. J.3; De donno, M.2; Mariotti, M. L.2; Occhipinti, M.4; Barsotti, M.5; Scatena, F.2; Marchetti, P.4; Boggi, U.1 Author Information
To implement the regional guidelines on management of diabetic foot (DF) into real practice, diabetiologists working in public diabetologic services Tuscany Region Health Service launched an bottom-up initiative called Diabetic Foot Valley, aiming creating a community practice for DF care Tuscany, Italy.
Glucagon-like peptide-1 receptor (GLP-1R) agonists are being used for the treatment of type 2 diabetes (T2D) and may have beneficial effects on pancreatic β-cells. Here, we evaluated GLP-1R agonism insulin secretory granule (ISG) dynamics in primary β-cells isolated from human islets exposed to palmitate-induced lipotoxic stress. Islets cells were 48 h 0.5 mM palmitate (hereafter, ‘Palm’) with or without addition a GLP-1 agonist, namely 10 nM exendin-4 ‘Ex-4’). Dissociated first transfected...
Researchers have demonstrated in a decadelong study that pancreas transplantation alone (PTA) can be effective and safe for patients with type 1 diabetes mellitus (T1DM), the caveat this advance benefits select, not all, T1DM.